Literature DB >> 18764757

Reduction of hypoxia by perfluorocarbon emulsion in a traumatic spinal cord injury model.

Jason L Schroeder1, Jason M Highsmith, Harold F Young, Bruce E Mathern.   

Abstract

OBJECT: Few therapies have consistently demonstrated effectiveness in preserving O2 delivery after spinal cord injury (SCI). Perfluorocarbons (PFCs) offer great promise to carry and deliver O2 more efficiently than conventional measures. The authors investigated the use of Clark-type microelectrodes to monitor spinal cord oxygenation directly (intraparenchymal [IP] recording) and indirectly (cerebrospinal fluid [CSF] recording) in the context of SCI, O2 therapy, and PFC treatment.
METHODS: After placement of a subdural/CSF Licox probe in rats, incremental increases in the fraction of inspired O2 (FiO2) up to 100% were administered to establish a dose-response curve. The probe was then placed in the parenchyma of the same animals for a second dose-response curve. In a second study, rats with CSF or IP probes underwent SCI with the NYU Impactor and treatment with O2, followed by administration of PFC, or saline in the control group.
RESULTS: All animals in the first experiment responded to the FiO2 dose increase, with changes in PO2 evident in both CSF and IP levels. The SCI in the second experiment caused a marked drop in PO2 from a mean of 21.4 to 10.4 mm Hg, with most animals dropping to less than half their preinjury value. All animals responded to 100% O2 treatment. Every animal that received PFCs showed significant improvement, with a mean increase in PO2 of 23.3 mm Hg. Only 1 saline-treated animal showed any benefit. Oxygen values in the PFC treatment group reached up to 6 times the normal level.
CONCLUSIONS: Oxygen levels in SCI show a profound drop almost immediately postinjury. Administration of PFCs combined with 100% O2 therapy can reverse tissue hypoxia and holds promise for reducing ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18764757     DOI: 10.3171/SPI/2008/9/8/213

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  6 in total

1.  Neuroprotective effects of perflurocarbon (oxycyte) after contusive spinal cord injury.

Authors:  Adly Yacoub; Marygrace C Hajec; Richard Stanger; Wen Wan; Harold Young; Bruce E Mathern
Journal:  J Neurotrauma       Date:  2013-11-21       Impact factor: 5.269

2.  The intravenous perfluorocarbon emulsion Oxycyte does not increase hyperbaric oxygen-related seizures in a non-sedated swine model.

Authors:  Richard T Mahon; Aaron Hall; Michael Bodo; Charles Auker
Journal:  Eur J Appl Physiol       Date:  2013-09-06       Impact factor: 3.078

Review 3.  Recent advances in the pharmacologic treatment of spinal cord injury.

Authors:  April Cox; Abhay Varma; Naren Banik
Journal:  Metab Brain Dis       Date:  2014-05-16       Impact factor: 3.584

4.  Pericytes impair capillary blood flow and motor function after chronic spinal cord injury.

Authors:  Yaqing Li; Ana M Lucas-Osma; Sophie Black; Mischa V Bandet; Marilee J Stephens; Romana Vavrek; Leo Sanelli; Keith K Fenrich; Antonio F Di Narzo; Stella Dracheva; Ian R Winship; Karim Fouad; David J Bennett
Journal:  Nat Med       Date:  2017-05-01       Impact factor: 53.440

5.  Preclinical Validation of the Therapeutic Potential of Glasgow Oxygen Level Dependent (GOLD) Technology: a Theranostic for Acute Stroke.

Authors:  Graeme A Deuchar; Josie C van Kralingen; Lorraine M Work; Celestine Santosh; Keith W Muir; Chris McCabe; I Mhairi Macrae
Journal:  Transl Stroke Res       Date:  2018-11-30       Impact factor: 6.829

6.  Functional, Metabolic and Morphologic Results of Ex Vivo Donor Lung Perfusion with a Perfluorocarbon-Based Oxygen Carrier Nanoemulsion in a Large Animal Transplantation Model.

Authors:  Ilhan Inci; Stephan Arni; Ilker Iskender; Necati Citak; Josep Monné Rodriguez; Miriam Weisskopf; Isabelle Opitz; Walter Weder; Thomas Frauenfelder; Marie Pierre Krafft; Donat R Spahn
Journal:  Cells       Date:  2020-11-18       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.